Wilson, Melissa

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

Peters, B. A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J. S., Osman, I., & Ahn, J. (2019) · Genome Medicine

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 263

Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.

Tolcher, A. W., Reeves, J. A., McKean, M., Chmielowski, B., Beck, J. T., Shaheen, M. F., Somaiah, N., Wilson, M., Spira, A. I., Drabick, J. J., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCancer-related Molecular Pathways

Cited by 23

Distinct sets of molecular characteristics define tumor-rejecting neoantigens

Adams, A. C., Macy, A. M., Borden, E. S., Herrmann, L. M., Brambley, C. A., Ma, T., Li, X., Hughes, A., Roe, D. J., Mangold, A. R., et al. (2024) · Journal for ImmunoTherapy of Cancer

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 4

Structural changes from wild-type define tumor-rejecting neoantigens

Adams, A. C., Macy, A. M., Borden, E. S., Herrmann, L. M., Brambley, C. A., Sonar, S. A., Ma, T., Li, X., Hughes, A., Roe, D. J., et al. (2025) · Journal for ImmunoTherapy of Cancer

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 4